… Axiomer Investor Call ProQR management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … the presentation date. Download the presentation About Axiomer ® ProQR is pioneering a next-generation RNA editing …
This month several ProQRians will attend the Oligonucleotide and Peptide Therapeutics Conference (TIDES Europe) 2022 to highlight our Axiomer RNA-editing platform technology.
… Investor/Analyst Webcast: Lilly Partnership Expansion and Axiomer Overview ProQR Management will host an investor … conference call and webcast to discuss the Company’s Axiomer RNA editing technology platform following the … 30 days following the presentation date. About Axiomer ® ProQR is pioneering a next-generation RNA base …
… focuses on developing potential medicines using our Axiomer RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer, closer to the clinic. Today we are delighted to … announced in September 2021 , applied ProQR’s proprietary Axiomer™ RNA editing platform to target disorders of the …
… the event, the Company will showcase its proprietary Axiomer ® RNA-editing technology platform, announce initial … and mentored over 50 Ph.D. and M.S. degree students. About Axiomer ® ProQR is pioneering a next-generation RNA base editing technology called Axiomer ® , which could potentially yield a new class of …
Bart Klein was at the forefront of ProQR's Axiomer® RNA editing technology development. This platform technology makes it possible to use the cells own machinery to reverse mutations that cause a genetic disease. Read the interview.
… ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple … ProQR will focus exclusively on the development of the Axiomer® RNA editing technology platform across multiple …
… focuses on developing potential medicines using our Axiomer™ RNA editing platform technology. Strategic … drive the advancement of an early-stage technology, like Axiomer , closer to the clinic. In any global licensing and …
